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treated. The savings mainly resulted from shorter operating time (13 Minutes) and 
decreased hospital stay (0.7 days). ConClusions: Although the instrument cost 
is higher for the ultrasonic device, the total procedural cost is lower compared 
to electrosurgery. Utilization of the Harmonic® ultrasonic device in laparoscopic 
cholecystectomy can lead to substantial cost savings for US hospitals.
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objeCtives: To examine the mortality and medical costs during the first and the 
2nd year following the onset of the five liver-related diseases, i.e. HCV infection, 
compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carci-
noma (HCC), or liver transplantation. Methods: Patients with HCV infection and 
patients who transitioned to the health state of liver-related disease were identi-
fied from the National Health Insurance Research Database (NHIRD) during 2008-
2010 if any outpatient/inpatient service with primary diagnosis code of 070.54 for 
HCV infection or 571.5 for CC occurred, or if patients registered in the Registry of 
Catastrophic Illness with diagnosis code of 571.5 for DCC, 155 for HCC or V42.7 for 
post liver transplantation. Dual infection patients with diagnosis code of 070.30 for 
HBV or 042-044 for HIV were excluded. The date that the outpatient visit/admission 
with the diagnosis code associated with each health state of liver-related disease 
firstly occurred was defined as the index date. Regression-adjusted medical costs 
associated with each health state of liver-related disease within 1st year and 2ndyear 
after the index date were estimated by generalized linear regression model. Excess 
risks of death for patients with DCC, HCC, or liver transplantation were assessed 
by Cox proportional hazard model. Results: First year total medical costs associ-
ated with HCV infection, CC, DCC, HCC and liver transplantation were NT$25,345, 
NT$49,793, NT$187,428, NT$197,835, NT$487,816, respectively. The 2nd year total 
medical costs associated with DCC, HCC and liver transplant were NT$194,016, 
NT$176,167 and NT$270,009, respectively. Patients in the health states of DCC, HCC 
and liver transplantation posed higher risk of death with hazard ratio of 14.5when 
compared with their matched control counterparts. ConClusions: Liver-related 
diseases followed by HCV infection impose substantial economic burdens to the 
National Health Insurance in Taiwan. Effective treatment for HCV infection may 
imply potential savings to the society.
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objeCtives: To describe health care resource utilization in treating patients 
affected by inflammatory bowel diseases (IBD) and to assess the related direct costs 
to the Italian health care system (HS) in its most populated region. Methods: A 
retrospective observational study was conducted using data from DENALI, a data 
warehouse that organizes and integrates the health care administrative databases 
of the national HS in Lombardy (northern Italy) with a probabilistic approach. The 
Italian HS provides universal coverage and records the accesses to health care ser-
vices at regional level. We enrolled adult patients with Ulcerative Colitis (UC) or 
Crohn’s Disease (CD) diagnosed during the period 2003-2009. Patients were classi-
fied in two cohorts in relation to the type of IBD and were followed until December 
31st, 2009 to assess the mean annual consumption of resources (hospitalizations, 
pharmaceutical prescriptions, outpatient services) and the related costs incurred by 
HS. Results: We identified 5,523 patients with UC and 3,321 with CD and the mean 
annual cost per-capita was € 2,386 (95%CI: 2,241-2,516) and € 2,699 (95%CI: 2,538-
2,914) respectively. The breakdown of expense was similar in the cohorts: pharma-
cological treatments accounted for 37% , hospitalizations for 47% and outpatient 
services for 16%. Use of mesalamine was high in patients with UC and CD:94% and 
88% of subjects was respectively prescribed at least one package during follow-up. 
High adherence (≥ 70%) to oral mesalamine was observed in 39% of patients with 
UC and in 24% of CD cohort. Less than 6% of patients used biologics, which were 
used only from 2008. ConClusions: This study confirms that patients with IBD 
represent a considerable economic burden for the Italian HS: prescribed drugs, 
especially mesalamine, account for a substantial proportion of health care costs. 
The results underline the importance of administrative databases and the need 
for further research, since the recent widespread use of biologics for treating IBD.
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objeCtives: Irritable bowel syndrome (IBS) is a common functional gastrointestinal 
disorder. We assessed utilisation of secondary care services and associated costs 
among patients with IBS. Methods: IBS was identified by medical diagnosis and/
or prescribing in the UK primary care setting. Patients had ≥ 12 months of medical 
history prior to diagnosis. Absolute resource use and expenditure were assessed 
post IBS and over four years (01/04/2008-31/03/2012) using Hospital Episode Statistic 
data. Inpatient admission, outpatient attendance and length of stay for any cause 
including IBS related conditions were assessed. Inpatient costs for the period were 
estimated using allocated Health Resource Group coded data. Outpatient costs 
considered were: clinical management of patient with HCV chronic infection, access 
modalities, outpatient visit, planned and unplanned visits, hospital admission, role of 
the general practitioner (GP). Results: The budget impact analysis shows that, consid-
ering both naïve and previously treated patients, the treatment with boceprevir has an 
impact on the National Health Service of almost € 66 million for the first year. Compared 
to treatment with DT, the cost-utility analysis shows for the boceprevir-based treatment 
strategy an ICER of € 8.622,00. The management of TT for its intrinsic complexity requires 
monthly outpatients visits, at least at the beginning of treatment, for monitoring the 
compliance to treatment, efficacy and side effects. A critical organizational point is 
potentially the request for boceprevir for each single patient by the medical prescriptor, 
who needs to fill in detailed form from the Italian Agency of Drug (AIFA). ConClusions: 
The impact of the introduction of boceprevir on the budget is high, even if the ICER is 
favourable. Patients’ management is particularly complex and there is the need for an 
alliance between the patients, their relatives, GPs and specialized centers.
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objeCtives: ED can be administered based on three different systems – powder 
based (Po), open, liquid (Op), and a completely closed (Cl). There are differences in the 
preparation, installation and delivery and in the diarrhea rates among them. Our aim 
was to measure the total costs for each system, considering the resources needed to 
prepare, delivery administer and discard of each system (hidden costs). Methods: 
We measured the human (nurse, nutritionist, auxiliary personnel) resources involved 
in ED preparations in three hospitals of Brazil. Then, we calculated the costs of the 
process, based on the minimum official wage for each professional category. After, we 
added the costs of the diets and materials needed to the infusion. We used as base 
case a daily need of 1 000Kcal / patient. Additional analyses were performed to include 
the side effects of ED system. Results: There were differences among the human 
resources needed for each system. Hidden costs were 63% of the total for Op, 58% for Po 
and 53% for Cl. Particularly, the nurse time varied from 18 minutes for Po and Op and 5 
min for Cl for each infusion. Considering that and average patient would require daily 
4 infusions of Po or Op, that represents a total of 72min of nurse time to these systems, 
against 5 min to Cl. Total daily costs, were Op US$ 62.05; Po US$ 50.75 and Cl US$48.03. 
If we consider the costs of side effects, such as diarrhea, the costs are: Op US$ 73.42; 
Po US$ 62.15 and Cl 56.35. This increase in the difference amog the costs is due to a 
lower incidence of diarrhea in Cl systems. ConClusions: There are many hidden 
costs on the ED systems. If we consider them Cl systems are less costly than Op and Po.
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objeCtives: Proton pump inhibitors (PPIs) are essential components schemes of 
antyhelicobacter therapy (AT) of peptic ulcer disease. The aim of research - to deter-
mine the costs of the use of PPIs in the traditional triple schemes AT (first and second 
line) of the working age patients with a duodenal ulcer in Ukraine. The objects of 
research - preparations of omeprazole, pantoprazole, rabeprazole, lansoprozol, ezome-
prazol, which are present in Ukraine. Methods: Cost analysis on the use of PPIs in 
the schemes of AT was performed per one patient for 14 days with the daily doses of 
drugs: omeprazole - 40 mg, pantoprazole - 80 mg, rabeprazole - 40 mg, lansoprozol - 60 
mg, ezomeprazol - 40 mg (according to the recommendations of the “Maastricht IV”, 
2010). For determining the costs only the costs of the PPIs were taken into account. 
The prices of drugs were taken from the information system “Drugs” of Company 
“Morion” (December, 2012). The currency ratio of UAH to dollar (USA) on 10.12.12 was 
7.99:1. To determine the range of costs for use of PPIs determined their trade names 
with the minimum and maximum costs for the AT. Results: The range of costs for 
use of PPIs in the traditional triple schemes AT in Ukraine is wide enough, respectively: 
omeprazole - 1.15 - 19.15 $, pantoprazole - 5.11 - 49.28 $, lansoprozol - 5.14 - 10.66 $, 
rabeprazole - 4.27 - 63.40$, ezomeprazol 1.81 - 36.42$. ConClusions: Costs only for 
the use of PPIs in the schemes of AT of duodenal ulcer can be quite high in Ukraine. 
In this regard, the choice of PPIs for inclusion in the schemes of AT is advisable to use 
the results of pharmacoeconomic studies that will optimize the costs of the payer.
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objeCtives: Harmonic® ultrasonic energy devices have been developed as a safer 
and more efficient alternative to traditional electrosurgery (monopolar and bipolar) 
in laparoscopic cholecystectomy. However, the economic impact on hospital cost 
has not yet been assessed in the United States. The aim of the study is to evaluate 
the total cost of laparoscopic cholecystectomy performed with an ultrasonic device 
versus electrosurgery from a hospital perspective. Methods: A literature review 
was performed to identify publications via EMBASE and MEDLINE database. Nine 
randomized controlled studies were included in this analysis based on inclusion 
criteria. The clinical results were weighted based on No. of patients to calculate 
averages for both energy devices. The total departmental cost data for electrosurgery 
group were obtained from a large US payor (PREMIER database) to apply the clini-
cal findings to calculate the cost for the Harmonic group. The total cost in laparo-
scopic cholecystectomy with two energy devices was compared to determine which 
modality is more cost effective. Results: The total case cost using an ultrasonic 
device in an inpatient laparoscopic cholecystectomy is $7701 v.s. electrosurgery is 
$8637. The use of an ultrasonic device provides a hospital savings of $936 per patient 
